Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes. Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain. Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
